Yvonne Westermaier

Yvonne Westermaier

Auto-generated profile, based on publicly available information

Yvonne Westermaier

Boehringer Ingelheim (Austria)

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 April 2011 in British Journal of Pharmacology
Verified
Journal Article
Open access
PDF file
Vincent JaquetVincent Jaquet
Vincent Jaquet
JMJulien Marcoux
Julien Marcoux
EFEric Forest
Eric Forest
KLKevin G Leidal
Kevin G Leidal
SMSally McCormick
Sally McCormick
KBKaren Bedard
Karen Bedard
BACKGROUND Celastrol is one of several bioactive compounds extracted from the medicinal plant Tripterygium wilfordii. Celastrol is used to treat inflammatory conditions, and shows benefits in models of neurodegenerative disease, cancer and arthritis, although its mechanism of action is incompletely understood.EXPERIMENTAL APPROACH Celastrol was tested on human NADPH oxidases (NOXs) using a panel of experiments: production of reactive oxygen species and oxygen consumption by NOX enzymes, xanthine oxidase activity, cell toxicity, phagocyte oxidase subunit translocation, and binding to cytosolic subunits of NOX enzymes. The effect of celastrol was compared with diphenyleneiodonium, an established inhibitor of flavoproteins.KEY RESULTS Low concentrations of celastrol completely inhibited NOX1, NOX2, NOX4 and NOX5 within minutes with concentration–response curves exhibiting higher Hill coefficients and lower IC50 values for NOX1 and NOX2 compared with NOX4 and NOX5, suggesting differences in their mode of action. In a cell‐free system, celastrol had an IC50 of 1.24 and 8.4 µM for NOX2 and NOX5, respectively. Cytotoxicity, oxidant scavenging, and inhibition of p47phox translocation could not account for NOX inhibition. Celastrol bound to a recombinant p47phox and disrupted the binding of the proline rich region of p22phox to the tandem SH3 domain of p47phox and NOXO1, the cytosolic subunits of NOX2 and NOX1, respectively.CONCLUSIONS AND IMPLICATIONS These results demonstrate that celastrol is a potent inhibitor of NOX enzymes in general with increased potency against NOX1 and NOX2. Furthermore, inhibition of NOX1 and NOX2 was mediated via a novel mode of action, namely inhibition of a functional association between cytosolic subunits and the membrane flavocytochrome.

1 January 2015 in Methods
Verified
Journal Article
Closed access
YWYvonne Westermaier
Yvonne Westermaier
XBXavier Barril
Xavier Barril
LSLeonardo Scapozza
Leonardo Scapozza

3 July 2024 in ACS Chemical Biology
Verified
Journal Article
Closed access
VVVesna Vetma
Vesna Vetma
LPLaura Casares Perez
Laura Casares Perez
JEJán Eliaš
Ján Eliaš
ASAndrea Stingu
Andrea Stingu
AKAnju Kombara
Anju Kombara
MKManfred Koegl
Manfred Koegl

15 July 2017 in Journal of Computer-Aided Molecular Design
Verified
Journal Article
Closed access
PDF file
YWYvonne Westermaier
Yvonne Westermaier
SRSergio Ruiz-Carmona
Sergio Ruiz-Carmona
ITIsabelle Theret
Isabelle Theret
FPFrançoise Perron-Sierra
Françoise Perron-Sierra
GPGuillaume Poissonnet
Guillaume Poissonnet
XBXavier Barril
Xavier Barril

20 June 2025 in Journal of Chemical Information and Modeling
Verified
Journal Article
Closed access
OHOleksandra Herasymenko
Oleksandra Herasymenko
MSMadhushika Silva
Madhushika Silva
AAAbd Al-Aziz A. Abu-Saleh
Abd Al-Aziz A. Abu-Saleh
AAAyaz Ahmad
Ayaz Ahmad
JAJesus Alvarado-Huayhuaz
Jesus Alvarado-Huayhuaz
MSMatthieu Schapira
Matthieu Schapira

3 July 2019 in Journal of Computer-Aided Molecular Design
Verified
Journal Article
Closed access
PDF file
DSDaniel Soler
Daniel Soler
YWYvonne Westermaier
Yvonne Westermaier
RSRobert Soliva
Robert Soliva